pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 6·1 min read
save

OpenAI’s health AI policy blueprint seen as reasonable yet self‑serving, experts say

May 6, 2026·read at STAT ↗RegulatoryNegative

OpenAI has expanded its health‑focused AI tools, rolling out ChatGPT Health for consumers, a hospital‑oriented ChatGPT for Healthcare, and a version for clinicians. Alongside the clinician chatbot, the company released a policy blueprint that outlines how it believes AI can transform the broader health‑care system.

Industry observers say the proposals contain sensible ideas, such as encouraging data sharing and clear safety standards. However, they also note that many of the recommendations would keep the market open for OpenAI’s own products and limit stricter regulation that could affect competitors.

Harvard health‑policy professor David Blumenthal described the effort as trying to “have their cake and eat it too,” suggesting OpenAI wants to appear responsible while preserving commercial advantages. Critics warn that the self‑interest embedded in the blueprint could shape future health‑AI rules in ways that favor the company.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: OpenAI wants to ‘have their cake and eat it too’ with health AI policy recommendations”

read at STAT ↗
491 words · retrieved May 8
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING
drugs
Obesity
topics
Obesity

related stories

  • Jun 9Diabetes Association in uproar after members expelled from annual meeting over protest of NIH cutsSTAT
  • Jun 8#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotEndpoints
  • Jun 8Opinion: American horses are obese, tooSTAT
  • Jun 7STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADASTAT
  • Jun 6STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet endingSTAT